Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
allo-APZ2-DFU for Diabetic Neuropathic Ulcer
NCT03267784Phase 2Completed
- Sponsor
- RHEACELL
- Start
- Nov 2017
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EBESANAR in diabetic foot ulcer (DFU), sponsored by RHEACELL. Primary endpoints: Percentage of wound surface area reduction at 12 weeks and Assessment of adverse event (AE) occurrence at 12 months. Started Nov 2017; status: completed.
02
Drugs
EBESANAR
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT03267784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267784.